News AstraZeneca and Lilly’s Alzheimer’s drug fails trial The battle to develop a drug to treat Alzheimer’s disease has been dealt a blow following disappointing phase 3 trial results.
News Biogen’s Alzheimer’s drug, elenbecestat, shows early promise A trial of Biogen’s Alzheimer’s disease drug elenbecestat has had promising results in mild to moderate forms of the disease.
News vTv's azeliragon is latest Alzheimer's drug failure vTv to stop all studies after STEADFAST trial failure
News Celgene pursues neuro breakthrough with $150m Prosena deal Celgene is pushing further into the field of neuroscience and dementia research with an alliance with Dublin-based biotech Prosena.
Views & Analysis Digital in action against Alzheimer’s disease Digital technologies are both helping to transform the public’s perception of dementia, and enabling everyone to help scientific research into the disease by playing a smartphone game that tests navigation skills.
News Concerns mount over Biogen Alzheimer's drug FDA announces guidance to encourage development of new drugs
News Lilly bags FDA okay for Wegovy pill rival orforglipron Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
